IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Cullen Investment Group LTD.

Cullen Investment Group LTD. grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 20,575 shares of the medical research company’s stock after buying an additional 267 shares during the quarter. Cullen Investment Group LTD.’s holdings in IQVIA were worth $4,043,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Private Advisor Group LLC raised its holdings in IQVIA by 8.1% in the 2nd quarter. Private Advisor Group LLC now owns 5,078 shares of the medical research company’s stock valued at $1,074,000 after acquiring an additional 379 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of IQVIA by 110.7% in the second quarter. Acadian Asset Management LLC now owns 7,078 shares of the medical research company’s stock valued at $1,496,000 after buying an additional 3,718 shares during the period. Parallel Advisors LLC raised its position in IQVIA by 3.5% during the second quarter. Parallel Advisors LLC now owns 8,859 shares of the medical research company’s stock valued at $1,873,000 after purchasing an additional 296 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its position in IQVIA by 16.5% during the second quarter. Thompson Siegel & Walmsley LLC now owns 18,292 shares of the medical research company’s stock valued at $3,868,000 after acquiring an additional 2,592 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of IQVIA by 1.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 140,039 shares of the medical research company’s stock worth $29,610,000 after acquiring an additional 2,576 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.6 %

Shares of IQVIA stock opened at $204.50 on Tuesday. The stock has a market cap of $37.12 billion, a PE ratio of 26.84, a price-to-earnings-growth ratio of 2.05 and a beta of 1.48. The firm has a fifty day moving average price of $201.73 and a 200 day moving average price of $221.71. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on IQV shares. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research report on Wednesday, December 11th. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research note on Tuesday, November 5th. Leerink Partners reissued an “outperform” rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Finally, Redburn Atlantic started coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $255.82.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.